Impact of Lactobacillus paracasei IMC502 in coculture with traditional starters on volatile and non-volatile metabolite profiles in yogurt

2020 ◽  
Vol 99 ◽  
pp. 61-69 ◽  
Author(s):  
Yuxiang Gu ◽  
Xing Li ◽  
Ran Xiao ◽  
Olayemi Eyituoyo Dudu ◽  
Lin Yang ◽  
...  
2010 ◽  
Vol 5 (1) ◽  
pp. 1934578X1000500 ◽  
Author(s):  
Niko S. Radulović ◽  
Polina D. Blagojević ◽  
Danielle Skropeta ◽  
Aleksandra R. Zarubica ◽  
Bojan K. Zlatković ◽  
...  

Tansy, Tanacetum macrophyllum (Waldst. & Kit.) Sch. Bip., is often misidentified by herb collectors as yarrow, Achillea grandifolia Friv. With the former, cases of poisoning induced by its ingestion are well documented, but the latter is widely used for ethnopharmacological purposes. The aim of this study was to estimate, based on the volatile metabolite profiles of the two species, the potential health risk connected with their misidentification. GC and GC-MS analysis of the essential oils hydrodistilled using a Clevenger-type apparatus from A. grandifolia, T. macrophyllum, and two plant samples (reputedly of A. grandifolia, but in fact mixtures of A. grandifolia and T. macrophyllum) obtained from a local market, resulted in the identification of 215 different compounds. The main constituents of A. grandifolia oil were ascaridole (15.5%), α-thujone (7.5%), camphor (15.6%), borneol (5.2%) and (Z)-jasmone (6.4%), and of T. macrophyllum oil, 1,8-cineole (8.6%), camphor (6.4%), borneol (9.1%), isobornyl acetate (9.5%), copaborneol (4.2%) and γ-eudesmol (6.2%). The compositions of the oils extracted from the samples obtained from the market were intermediate to those of A. grandifolia and T. macrophyllum. Significant differences in the corresponding volatile profiles and the literature data concerning the known activities of the pure constituents of the oils, suggested that the pharmacological action of the investigated species (or their unintentional mixtures) would be notably different. It seems, however, that misidentification of T. macrophyllum as A. grandifolia does not represent a health risk and that the absence of the toxic α-thujone from T. macrophyllum oil may in fact be regarded as a benefit.


2011 ◽  
Vol 4 (7) ◽  
pp. 486-488
Author(s):  
Manal A Hassan ◽  
◽  
Saad S Fakhry ◽  
Abood H Moslah ◽  
Zahraa A Jabur

2003 ◽  
Author(s):  
Charles Thomas Parker ◽  
Dorothea Taylor ◽  
George M Garrity

Molecules ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 472
Author(s):  
Ali Osman ◽  
Nashwa El-Gazzar ◽  
Taghreed N. Almanaa ◽  
Abdalla El-Hadary ◽  
Mahmoud Sitohy

The current study investigates the capacity of a lipolytic Lactobacillus paracasei postbiotic as a possible regulator for lipid metabolism by targeting metabolic syndrome as a possibly safer anti-obesity and Anti-dyslipidemia agent replacing atorvastatin (ATOR) and other drugs with proven or suspected health hazards. The high DPPH (1,1-diphenyl-2-picrylhydrazyl) and ABTS [2,2′-azino-bis (3-ethyl benzothiazoline-6-sulphonic acid)] scavenging activity and high activities of antioxidant enzyme such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-px) of the Lactobacillus paracasei postbiotic (cell-free extract), coupled with considerable lipolytic activity, may support its action against metabolic syndrome. Lactobacillus paracasei isolate was obtained from an Egyptian cheese sample, identified and used for preparing the postbiotic. The postbiotic was characterized and administered to high-fat diet (HFD) albino rats (100 and 200 mg kg−1) for nine weeks, as compared to atorvastatin (ATOR; 10 mg kg−1). The postbiotic could correct the disruption in lipid metabolism and antioxidant enzymes in HFD rats more effectively than ATOR. The two levels of the postbiotic (100 and 200 mg kg−1) reduced total serum lipids by 29% and 34% and serum triglyceride by 32–45% of the positive control level, compared to only 25% and 35% in ATOR’s case, respectively. Both ATOR and the postbiotic (200 mg kg−1) equally decreased total serum cholesterol by about 40% and 39%, while equally raising HDL levels by 28% and 30% of the positive control. The postbiotic counteracted HFD-induced body weight increases more effectively than ATOR without affecting liver and kidney functions or liver histopathology, at the optimal dose of each. The postbiotic is a safer substitute for ATOR in treating metabolic syndrome.


Sign in / Sign up

Export Citation Format

Share Document